CD133 Overview
Molecule Name
CD133
Synonyms
CD133,PROM1,PROML1,Prominin-1,AC133
Drug Development Progress
Drugs in Clinical Trials2
Approved Drugs0
Highest Development StagePhase 2 Clinical
Target Synonym
Antigen AC133，Prominin-1，PROM1，Prominin 1，Prominin-Like Protein 1，PROML1，Stargardt Disease 4 (Autosomal Dominant)，Hematopoietic Stem Cell Antigen，Macular Dystrophy， Retinal 2，Prominin (Mouse)-Like 1，CD133 Antigen，HProminin，MSTP061，CORD12，AC133，CD133，MCDR2，STGD4，RP41，AC133 Antigen
Background
Prominin-1 is also known as CD133, Antigen AC133, PROM1, PROML1 and MSTP061. Is used as marker for hematopoietic stem and progenitor cells (HSPC) for somatic stem cell isolation. May play a role in cell differentiation, proliferation and apoptosis . Binds cholesterol in cholesterol-containing plasma membrane microdomains and may play a role in the organization of the apical plasma membrane in epithelial cells. During early retinal development acts as a key regulator of disk morphogenesis. Involved in regulation of MAPK and Akt signaling pathways. In neuroblastoma cells suppresses cell differentiation such as neurite outgrowth in a RET-dependent manner.
CD133 Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| P-134 | P-134; P134 | Phase 2 Clinical | Tianjin Tasly Pharmaceutical Co Ltd | Glioblastoma | Details |
| anti-CD133-CAR vector-transduced T cells | Phase 2 Clinical | Pla General Hospital | Brain Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Liver Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |